Drug Profile
VTP 27999
Alternative Names: VTP-27999Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Vitae Pharmaceuticals
- Class Antihypertensives; Small molecules
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension; Kidney disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 May 2016 Chemical information added
- 07 Jan 2015 Discontinued - Phase-I for Kidney disorders in USA (PO)